<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162656</url>
  </required_header>
  <id_info>
    <org_study_id>FAB LMB96</org_study_id>
    <nct_id>NCT00162656</nct_id>
  </id_info>
  <brief_title>Treatment of Mature B-cell Lymphoma/Leukaemia</brief_title>
  <official_title>Treatment of Mature B-cell Lymphoma/Leukaemia A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international trial conducted by three cooperative groups: SFOP (France, Belgium,
      Netherlands), CCG (USA, Canada, Australia), and UKCCSG (UK and Ireland). Children with mature
      B-cell lymphoma/leukaemia are stratified into three different risk groups (A, B, C) and
      receive treatment of progressive intensity. Randomized trials in the 2 biggest groups (B and
      C) test whether &quot;reduced&quot; therapy is equivalent to standard intensive therapy (LMB-89 B and
      C) in terms of event free survival. The reason for the modification is to reduce the long
      term toxicity which includes cardiotoxicity, impaired fertility and secondary malignancy. In
      group B, the modifications of treatment consists of a reduction of cyclophosphamide in
      COPADM2 and/or the elimination of COPADM3. In group C, the modification consists in a
      reduction of the doses in the CYVE courses and the elimination of the last 3 courses of
      maintenance treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group B: Randomized trial with factorial design. The 4 treatment arms are standard LMB89
      therapy B, reduction of cyclophosphamide (CPM) in COPADM2, deletion of COPADM3, both
      reduction and deletion. Randomization occurs following COPADM1 and is stratified for national
      group, histology (large cell; small non cleaved cell) and stage (Murphy I orII; Murphy
      III+LDH&lt;2N; Murphy III+LDH&gt;2N or Murphy IV).

      The primary analysis questions are whether reducing CPM dose in COPADM2 results in a smaller
      long-term EFS whether omitting COPADM3 results in a smaller long-term EFS

      Group C: Randomized trial. The 2 treatment arms are standard LMB89 therapy C versus reduction
      of CYVE + deletion of the last 3 maintenance courses. Randomization occurs following COPADM2
      and is stratified for national group, histology (large cell; small non cleaved cell) and CNS
      disease.

      The primary analysis question is whether reducing CYVE and omitting the last 3 maintenance
      courses result in a smaller long-term EFS than standard LMB 89 treatment C
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Event free survival (event = progressive disease or relapse or second malignancy or death from any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long term toxicity</measure>
    <time_frame>10 years</time_frame>
    <description>long term toxicity: cardiotoxicity, impaired fertility, secondary malignancy</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">848</enrollment>
  <condition>B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Standard LMB B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LMB B without COPADM3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LMB B with half cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LMB B without COPADM3 and with half cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LMB C standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LMB C with mini CYVE and without 3 maintenance courses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>half cyclophosphamide</intervention_name>
    <arm_group_label>LMB B with half cyclophosphamide</arm_group_label>
    <arm_group_label>LMB B without COPADM3 and with half cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>without COPADM3</intervention_name>
    <arm_group_label>LMB B without COPADM3</arm_group_label>
    <arm_group_label>LMB B without COPADM3 and with half cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mini CYVE, without 3 maintenance courses</intervention_name>
    <arm_group_label>LMB C with mini CYVE and without 3 maintenance courses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMB B</intervention_name>
    <arm_group_label>Standard LMB B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMB C</intervention_name>
    <arm_group_label>LMB C standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed B lineage non-Hodgkin's lymphoma with Revised European American
             Lymphoma (REAL) II 9 (diffuse large cell lymphoma), 10 (Burkitt's lymphoma), or 11
             (high grade B cell lymphoma, Burkitt's like) or bone marrow &gt; 5% L3 blasts.

          -  Pre treatment imaging studies adequate to document Murphy disease stage

          -  Group B and C patients are eligible for randomization (Therapy stratification by group
             : Group A=completely resected stage I or completely resected abdominal stage II
             lesions, Group B= All cases not eligible for Group A or Group C, Group C= Any CNS
             involvement and/or bone marrow involvement Â³ 25% blasts)

          -  Patients should be available for a minimum follow up of 36 months

          -  Informed consent prior to study entry

        Exclusion Criteria:

          -  Anaplastic large cell Ki 1 positive lymphomas

          -  Previous chemotherapy.

          -  Congenital immunodeficiency

          -  Prior organ transplantation

          -  Previous malignancy of any type

          -  Known HIV positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Patte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Morgan Stanley Childrens Hospital of New York Presbyterian, Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Gerrard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Morgan Stanley Childrens Hospital of New York Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>March 27, 2012</last_update_submitted>
  <last_update_submitted_qc>March 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

